Novel agents for treatment of relapsed/refractory Hodgkin lymphoma
| . | Target . | N . | ORR (%) . | CR (%) . | PFS . | OS . | Toxicity . | Citation . |
|---|---|---|---|---|---|---|---|---|
| Camidanlumab tesirine | Anti-CD25 ADC | 117 | 70.1 | 33.3 | 9.1 mo | ~ | Immune, GBS | Carlo-Stella et al.32 |
| Favezilumab (with pembrolizumab) | LAG3 Inhibitor | 34 | 29 | 9 | 10.7 mo | 25.7 mo | Thyroid, GI | Timmerman et al.33 |
| Lenalidomide | IMiD | 36 | 19.4 | 2.8 | 4 mo | 20 mo | Cytopenias, rash | Fehniger et al.35 |
| Lenalidomide + temsirolimus | IMiD, mTOR-I | 20 | 80 | 35 | 9.2 mo | 39.6 mo | Cytopenias | Major et al.37 |
| Everolimus | mTOR-I | 57 | 47 | 5 | 7.2 mo | NR | Cytopenias, fatigue | Johnston et al.36 |
| Ibrutinib (with nivolumab) | BTKi | 17 | 51.9 | 29.5 | 17.3 mo | ~ | Cytopenias, rash | Hanel et al.42 |
| Panobinostat | HDACi | 129 | 27 | 4 | 6.1 mo | 1-y OS: 78% | Cytopenias | Younes et al.38 |
| Vorinostat (with pembrolizumab) | HDACi | 32 | 72 | 34 | 8.9 mo | NR | Cytopenias, thyroiditis | Mei et al.40 |
| Tinostamustine | Alkylating deacetylase inhibitor | 20 | 40 | 10 | 3.8 mo | ~ | Cytopenias, CINV | Sureda et al.61 |
| . | Target . | N . | ORR (%) . | CR (%) . | PFS . | OS . | Toxicity . | Citation . |
|---|---|---|---|---|---|---|---|---|
| Camidanlumab tesirine | Anti-CD25 ADC | 117 | 70.1 | 33.3 | 9.1 mo | ~ | Immune, GBS | Carlo-Stella et al.32 |
| Favezilumab (with pembrolizumab) | LAG3 Inhibitor | 34 | 29 | 9 | 10.7 mo | 25.7 mo | Thyroid, GI | Timmerman et al.33 |
| Lenalidomide | IMiD | 36 | 19.4 | 2.8 | 4 mo | 20 mo | Cytopenias, rash | Fehniger et al.35 |
| Lenalidomide + temsirolimus | IMiD, mTOR-I | 20 | 80 | 35 | 9.2 mo | 39.6 mo | Cytopenias | Major et al.37 |
| Everolimus | mTOR-I | 57 | 47 | 5 | 7.2 mo | NR | Cytopenias, fatigue | Johnston et al.36 |
| Ibrutinib (with nivolumab) | BTKi | 17 | 51.9 | 29.5 | 17.3 mo | ~ | Cytopenias, rash | Hanel et al.42 |
| Panobinostat | HDACi | 129 | 27 | 4 | 6.1 mo | 1-y OS: 78% | Cytopenias | Younes et al.38 |
| Vorinostat (with pembrolizumab) | HDACi | 32 | 72 | 34 | 8.9 mo | NR | Cytopenias, thyroiditis | Mei et al.40 |
| Tinostamustine | Alkylating deacetylase inhibitor | 20 | 40 | 10 | 3.8 mo | ~ | Cytopenias, CINV | Sureda et al.61 |
BTKi, Bruton tyrosine kinase inhibitor; CINV, chemotherapy-induced nausea and vomiting; GBS, Guillain-Barre syndrome; GI, gastrointestinal; HDACi, histone deacetylase inhibitor; IMiD, immunomodulatory imide drug; mTOR-I, mammalian target of rapamycin inhibitor.